AQR Arbitrage’s Biotech Acquisition Company Class A Ordinary Shares BIOT Stock Holding History

AQR Arbitrage’s Portfolio BIOT Stock Details BIOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-351,148	Closed	-$3.55M	–	1249
2022 Q4	$3.55M	Hold	351,148	–	–	0.09%	301
2022 Q3	$3.48M	Hold	351,148	–	–	0.08%	357
2022 Q2	$3.48M	Buy	351,148 +250,000	+247%	+$2.45M	0.08%	332
2022 Q1	$996K	Hold	101,148	–	–	0.03%	485
2021 Q4	$995K	Hold	101,148	–	–	0.03%	630
2021 Q3	$985K	Buy	101,148 +12,283	+14%	+$119K	0.03%	454
2021 Q2	$859K	Buy	+88,865	New	+$863K	0.02%	512

AQR Arbitrage's BIOT Position: Q1 2023 in Review

AQR Arbitrage sold out of Biotech Acquisition Company Class A Ordinary Shares (BIOT) in Q1 2023, closing a stake of 351,148 shares — an estimated $3.55M sold.

AQR Arbitrage first reported a position in BIOT in Q2 2021 and held it in 7 quarters. The position peaked at $3.55M in Q4 2022. 0 funds tracked by Wall St. Rank hold BIOT as of Q1 2023.

AQR Arbitrage reported no remaining Biotech Acquisition Company Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
AQR Arbitrage sold 351,148 Biotech Acquisition Company Class A Ordinary Shares shares in Q1 2023, an estimated $3.55M.
AQR Arbitrage first reported a position in Biotech Acquisition Company Class A Ordinary Shares in Q2 2021 and held it in 7 quarters.
AQR Arbitrage's Biotech Acquisition Company Class A Ordinary Shares position peaked at $3.55M in Q4 2022.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Class A Ordinary Shares as of Q1 2023.

Based on AQR Arbitrage's 13F filing for Q1 2023, filed 15 May 2023.